CoChat

Selective COX-2 Inhibitors and Dual Acting Anti-inflammatory Drugs: Critical Remarks

Open access
Bertolini, A., Ottani, A., Sandrini, M. · 2002 · Current Medicinal Chemistry

The DOI matches its Crossref record.

Abstract

Non steroidal anti-inflammatory drugs (NSAIDs) are still the most commonly used remedies for rheumatic diseases. But NSAIDs produce serious adverse effects, the most important being gastric injury up to gastric ulceration and renal damage. Several strategies have been adopted in order to avoid these shortcomings, especially gastrointestinal toxicity. So, non steroidal anti-inflammatory drugs have been associated with gastroprotective agents that counteract the damaging effects of prostaglandin synthesis suppression: however, a combination therapy introduces problems of pharmacokinetics, toxicity, and patient s compliance. Also incorporation of a nitric oxide (NO)-generating moiety into the molecule of several NSAIDs was shown to greatly attenuate their ulcerogenic activity: however, several findings suggest a possible involvement of NO in the pathogenesis of arthritis and subsequent tissue destruction. A most promising approach seemed to be the preparation of novel NSAIDs, specific for the inducible isoform of cyclooxygenase (COX-2): they appear to be devoid of gastrointestinal toxicity, in that they spare mucosal prostaglandin synthesis. However, a number of recent studies raised serious questions about the two central tenets that support this approach, namely that the prostaglandins that mediate inflammation and pain are produced solely via COX-2 and that the prostaglandins that are important in gastrointestinal and renal function are produced solely via COX-1. So, increasing evidence shows that COX-2 (not only COX-1) also plays a physiological role in several body functions and that, conversely, COX-1 (not only COX-2) may also be induced at sites of inflammation. Moreover, COX-2 selective NSAIDs have lost the cardiovascular protective effects of non-selective NSAIDs, effects which are mediated through COX-1 inhibition (in addition, COX-2 has a role in sustaining vascular prostacyclin production). The products generated by the 5-lipoxygenase pathway (leukotrienes) are particularly important in inflammation: indeed, leukotrienes increase microvascular permeability and are potent chemotactic agents; moreover, inhibition of 5-lipoxygenase indirectly reduces the expression of TNF-alpha (a cytokine that plays a key role in inflammation). This explains the efforts to obtain drugs able to inhibit both 5-lipoxygenase and cyclooxygenases: the so-called dual acting anti-inflammatory drugs. Such compounds retain the activity of classical NSAIDs, while avoiding their main drawbacks, in that curtailed production of gastroprotective prostaglandins is associated with a concurrent curtailed production of the gastro-damaging and bronchoconstrictive leukotrienes. Moreover, thanks to their mechanism of action, dual acting anti-inflammatory drugs could not merely alleviate symptoms of rheumatic diseases, but might also satisfy, at least in part, the criteria of curative drugs. Indeed, leukotrienes are pro-inflammatory, increase microvascular permeability, are potent chemotactic agents and attract eosinophils, neutrophils and monocytes into the synovium. Finally, recent data strongly suggest that dual inhibitors may have specific protective activity also in neurodegeneration.

Overview

Integrity signals

Registry

Crossref · 10.2174/0929867024606650

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Still being checked.

Cited by

See all 183

Metadata

Authors
Bertolini, A., Ottani, A., & Sandrini, M.
Affiliations
University of Modena and Reggio Emilia (IT)
Corresponding author
Sandrini, M.
Venue
Current Medicinal Chemistry
Published
2002-05-01
Volume
9
Issue
10
Pages
1033-1043
ISSN
0929-8673 (ISSN-L)
OpenAlex
W2123833658
Cited by
158
References
0
Citations by year
2025: 4 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 4 · 2018: 11 · 2017: 13 · 2016: 11 · 2015: 11 · 2014: 8 · 2013: 5 · 2012: 12
FWCI
1.21
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Current Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
COX-2 inhibitors, nonsteroidal anti-inflammatory drugs, cyclooxygenase-1, cyclooxygenase-2, 5-lipoxygenase inhibition, leukotrienes, prostaglandins, gastrointestinal toxicity, nephrotoxicity, cardioprotection, prostacyclin, TNF-α, rheumatic diseases, adverse drug reactions, nitric oxide, gastroprotective agents
MeSH terms
Animals, Anti-Inflammatory Agents, Non-Steroidal, Capillary Permeability, Gastrointestinal Diseases, Humans, Isoenzymes, Lipoxygenase, Membrane Proteins, Pain, Prostaglandin-Endoperoxide Synthases, Rheumatic Diseases, Synovial Membrane, Leukotrienes, Cyclooxygenase Inhibitors, Neurodegenerative Diseases, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective COX-2 Inhibitors and Dual Acting Anti-inflammatory Drugs: Critical Remarks. https://app.cochat.ai/papers/10.2174/0929867024606650
The paper
Bertolini, A., Ottani, A., & Sandrini, M. (2002). Selective COX-2 Inhibitors and Dual Acting Anti-inflammatory Drugs: Critical Remarks. Current Medicinal Chemistry. https://doi.org/10.2174/0929867024606650

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.